Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Johnson and Johnson
Argus Health
QuintilesIMS
Teva
Cantor Fitzgerald

Generated: July 15, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,795,725

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,795,725
Title:GABA analog prodrug sustained release oral dosage forms
Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(.alpha.-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
Inventor(s): Cundy; Kenneth C. (Redwood City, CA), Sastry; Srikonda (Sunnyvale, CA), Leung; Manshiu (Daily City, CA), Kadri; Balaji V. (Tampa, FL), Stach; Paul E. (Plymouth, MN)
Assignee: XenoPort, Inc. (Santa Clara, CA)
Application Number:11/269,045
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 8,795,725
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Composition; Use;

Drugs Protected by US Patent 8,795,725

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-002 Dec 13, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS ➤ Sign Up
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-002 Dec 13, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS ➤ Sign Up
Arbor Pharms Llc HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-001 Apr 6, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Colorcon
UBS
Merck
Citi
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.